A number of other research firms have also recently weighed in on MESO. Maxim Group set a $3.00 price objective on shares of Biopharmx and gave the stock a “buy” rating in a research report on Wednesday, June 12th. Zacks Investment Research cut shares of Home Bancshares from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. HC Wainwright reiterated a “buy” rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th. Finally, Chardan Capital set a $6.00 target price on shares of Mesoblast and gave the company a “hold” rating in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $12.13.
Shares of MESO stock traded down $0.01 during trading hours on Wednesday, hitting $5.24. The company’s stock had a trading volume of 10,069 shares, compared to its average volume of 49,893. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.92 and a current ratio of 1.92. The stock has a 50 day simple moving average of $5.08. Mesoblast has a 12-month low of $3.35 and a 12-month high of $8.78. The stock has a market cap of $494.39 million, a PE ratio of -8.38 and a beta of 1.86.
A hedge fund recently raised its stake in Mesoblast stock. Jane Street Group LLC grew its stake in shares of Mesoblast limited (NASDAQ:MESO) by 590.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 104,073 shares of the company’s stock after purchasing an additional 89,010 shares during the period. Jane Street Group LLC owned approximately 0.11% of Mesoblast worth $426,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.76% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Article: Dividend
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.